Similar articles for PMID: 21890591

Year	Number of Results
1962	1
1981	1
1988	1
1989	1
1991	1
1995	1
1997	2
1999	2
2000	1
2004	2
2006	3
2007	2
2008	7
2009	3
2010	6
2011	4
2012	8
2013	6
2014	1
2015	3
2016	1
2019	1
2020	1
2021	1
2022	2
2024	0

1

Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681.

te Beek ET, Moerland M, de Boer P, van Nueten L, de Kam ML, Burggraaf J, Cohen AF, van Gerven JM. te Beek ET, et al. J Psychopharmacol. 2012 Aug;26(8):1119-27. doi: 10.1177/0269881111415733. Epub 2011 Sep 2. J Psychopharmacol. 2012. PMID: 21890591 Clinical Trial.

2

Pharmacokinetics and central nervous system effects of the novel dopamine D3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state.

te Beek ET, Zoethout RW, Bani MS, Andorn A, Iavarone L, Klaassen ES, Fina P, van Gerven JM. te Beek ET, et al. J Psychopharmacol. 2012 Feb;26(2):303-14. doi: 10.1177/0269881111431750. Epub 2012 Jan 4. J Psychopharmacol. 2012. PMID: 22219221 Clinical Trial.

3

Differential responses to JNJ-37822681, a specific and fast dissociating dopamine D2 receptor antagonist, in cynomolgus monkey and Sprague-Dawley rat general toxicology studies: clinical observations, prolactin levels, mammary histopathology findings and toxicokinetics.

de Waal EJ, Desmidt M, Korte S, Niehoff M, Chase K, Arrowsmith W, Lampo A. de Waal EJ, et al. J Appl Toxicol. 2014 Sep;34(9):974-92. doi: 10.1002/jat.2916. Epub 2013 Sep 16. J Appl Toxicol. 2014. PMID: 24105799

4

The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects.

Liem-Moolenaar M, Zoethout RW, de Boer P, Schmidt M, de Kam ML, Cohen AF, Franson KL, van Gerven JM. Liem-Moolenaar M, et al. J Psychopharmacol. 2010 Nov;24(11):1671-9. doi: 10.1177/0269881109106942. Epub 2010 Feb 8. J Psychopharmacol. 2010. PMID: 20142308 Clinical Trial.

5

Central nervous system effects of haloperidol on THC in healthy male volunteers.

Liem-Moolenaar M, te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, Touw D, van Gerven JM. Liem-Moolenaar M, et al. J Psychopharmacol. 2010 Nov;24(11):1697-708. doi: 10.1177/0269881109358200. Epub 2010 Feb 8. J Psychopharmacol. 2010. PMID: 20142302 Clinical Trial.

6

Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.

Langlois X, Megens A, Lavreysen H, Atack J, Cik M, te Riele P, Peeters L, Wouters R, Vermeire J, Hendrickx H, Macdonald G, De Bruyn M. Langlois X, et al. J Pharmacol Exp Ther. 2012 Jul;342(1):91-105. doi: 10.1124/jpet.111.190702. Epub 2012 Apr 6. J Pharmacol Exp Ther. 2012. PMID: 22490380 Free article.

7

The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects.

Liem-Moolenaar M, Zoethout RW, de Boer P, Schmidt M, de Kam ML, Cohen AF, Franson KL, van Gerven JM. Liem-Moolenaar M, et al. J Psychopharmacol. 2010 Nov;24(11):1681-7. doi: 10.1177/0269881109105573. Epub 2009 Jul 31. J Psychopharmacol. 2010. PMID: 19648218 Clinical Trial.

8

In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography.

te Beek ET, de Boer P, Moerland M, Schmidt ME, Hoetjes NJ, Windhorst AD, van Berckel BN, Cohen AF, van Gerven JM, Lammertsma AA. te Beek ET, et al. J Psychopharmacol. 2012 Aug;26(8):1128-35. doi: 10.1177/0269881111435251. Epub 2012 Jan 30. J Psychopharmacol. 2012. PMID: 22290934

9

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.

de Haas SL, de Visser SJ, van der Post JP, de Smet M, Schoemaker RC, Rijnbeek B, Cohen AF, Vega JM, Agrawal NG, Goel TV, Simpson RC, Pearson LK, Li S, Hesney M, Murphy MG, van Gerven JM. de Haas SL, et al. J Psychopharmacol. 2007 Jun;21(4):374-83. doi: 10.1177/0269881106072343. Epub 2006 Nov 8. J Psychopharmacol. 2007. PMID: 17092968 Clinical Trial.

10

D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection.

Schmidt ME, de Boer P, Andrews R, Neyens M, Rossenu S, William Falteos D, Mannaert E. Schmidt ME, et al. Psychopharmacology (Berl). 2012 Dec;224(4):549-57. doi: 10.1007/s00213-012-2782-1. Epub 2012 Jul 7. Psychopharmacology (Berl). 2012. PMID: 22773165 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

53 results

Results by year